更新日：令和4(2022)年6月27日

内科-業績

原著

1. Imamura S, Hirai K, Hirai A.The glucagon-like peptide-1 receptor agonist,
   liraglutide, attenuatestheprogression of  overt diabetic nephropathy in
   type 2 diabetic patients. Tohoku J Exp Med. 2013; 231(1): 57-61.
2. Hirai K, Imamura S, Hirai A et al.Effects of once-weekly  dulaglutide
   on glycemic control and renal function inpatients with advanced-stage
   diabetic nephropathy. Nephro-Urol Mon 2017; 9(5) : e55058.

発表(国際学会）

1. Imamura S, Hirai A et al. A novel therapeutic use of glucagon-like peptide1
   receptor agonist for the treatment of overt diabetic nephropathy in
   patients with type 2 diabetes.第72回アメリカ糖尿病学会(2012年6月,フィラデ
   ルフィア)
2. Imamura S, Hirai A et al . A novel therapeutic use of liraglutide for the
   prevention of progression of overt diabetic nephropathy in patients with
   type 2 diabetes. 第73回アメリカ糖尿病学会(2013年6月, シ力ゴ)